<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-D2B1XWED/44211d29-c832-423b-8b95-8de1cb7ef88c/HTML"><dcterms:extent>48 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-D2B1XWED/a0a4fbe5-9f52-4b1a-b74e-6a1364f02a3d/PDF"><dcterms:extent>166 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-D2B1XWED/5b12e9d4-510e-4d5b-a4a8-fcfe3bb71afc/TEXT"><dcterms:extent>44 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-D2B1XWED"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2013</dcterms:issued><dc:creator>Lah Turnšek, Tamara</dc:creator><dc:creator>Motaln, Helena</dc:creator><dc:creator>Obrez, Mateja</dc:creator><dc:creator>Verbovšek, Urška</dc:creator><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:82</dc:format><dc:format xml:lang="sl">str. 113-122</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:2802255</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-D2B1XWED</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">celična terapija</dc:subject><dc:subject xml:lang="en">cell therapy</dc:subject><dc:subject xml:lang="en">glioblastoma multiformae</dc:subject><dc:subject xml:lang="sl">gliom</dc:subject><dc:subject xml:lang="sl">matične celice</dc:subject><dc:subject xml:lang="en">mesenchymal stem cells</dc:subject><dc:subject xml:lang="sl">mezenhimske matične celice</dc:subject><dc:subject xml:lang="sl">tumorji</dc:subject><dc:subject xml:lang="sl">tumorske matične celice</dc:subject><dc:subject xml:lang="en">tumour micro-environment</dc:subject><dc:subject xml:lang="en">tumour stem cells</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Vloga matičnih celic pri napredovanju in zdravljenju glioma| The role of stem cells in glioma progression and therapy|</dc:title><dc:description xml:lang="sl">The concepts of tumour origin and stochastic nature of carcinogenesis are being challenged today by hierarchical models that predict the existence of cancer stem cells (CSCs), which are postulated as unique cell population capable of infinite self renewal, multilineage differentiation and having a higher resistance to conventional cancer therapy thus facilitating malignant growth and therapy resistance. Accordingly, successful treatment of adult brain tumourglioma and its most malignant stageglioblastoma multiforme (GBM), would require the elimination of CSCs to avoid tumour relapse. Yet, with available therapy (i.e. surgery) in GBMs this cannot be achieved, due to infiltrative growth of a subpopluation of GBM cells with highly expressed migratory genes (migratome) into the normal brain tissue. Besides CSCs a proven prerequisite for tumour development and progression, tumour bulk mass also comprises haematopoietic stem cells, endothelial progenitor cells and mesenchymal stem cells (MSCs). The role of these other types of stem cell was shown to largely depend on the tumour microenvironment, where their contradictory anti-tumour action was evidenced. Yet, the exact mechanisms and MSCs role in cell-mediated modulation of tumour behaviour via paracrine and direct interactions with GBM (stem) cells still remain unknown. Nevertheless these stem cells, particularly MSCs, may represent novel therapeutic vectors for enhanced target-site delivery of chemotherapeutics, which are urgently needed to improve efficiency of current glioma treatment. So far, cell therapy using MSCs appears promising, due to MSCs selective tumour tropism and their immuno-modulatory potential regarding treatment of GBM, which will be discussed in this review</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-D2B1XWED"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-D2B1XWED" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-D2B1XWED/a0a4fbe5-9f52-4b1a-b74e-6a1364f02a3d/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-D2B1XWED/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-D2B1XWED" /></ore:Aggregation></rdf:RDF>